News
Important Only
Moderna falls after co withdraws application for COVID-flu combination vaccine
** Shares of vaccine maker Moderna MRNA.O fall 1.4% to $27.60 premarket ** Co says it is voluntarily withdrawing its marketing application for its COVID-flu combination vaccine for adults aged 50 years and older** Co plans to resubmit its application later this year, after late-stage efficacy data o...Reuters
Wed, May 21
US STOCKS-US stock futures dip, bond yields climb as Trump's tax bill faces test
Futures down: Dow 0.96%, S&P 500 0.71%, Nasdaq 0.72%Wolfspeed plunges after reports of potential bankruptcyTarget down after cutting annual sales forecastBy Shashwat Chauhan and Kanchana Chakravarty May 21 (Reuters) - U.S. stock index futures slipped and Treasury yields surged on Wednesday as...Reuters
Wed, May 21
BMO raises Deere PT on better 2026 profit forecast
** BMO Capital raise price target on agricultural-equipment maker Deere & Co DE.N to $460 from $425, a downside of 12.6% to the stock's last close** Rating unchanged at 'market perform'** BMO raises Deere's 2026 adj EPS forecast to $21.43 from $21.33 due to expected improved reta...Reuters
Wed, May 21
Is SoundHound AI Stock Primed to Soar?
You'll be hard-pressed to find a stock that's posting growth figures like SoundHound AI (NASDAQ: SOUN) stock. In the first quarter, it delivered jaw-dropping 151% year-over-year growth. Despite this strong growth, the stock is down nearly 50% year to date, and it hasn't seen near the recovery that m...The Motley Fool
Wed, May 21
Prediction: 5 Dividend Stocks That Could Crush the S&P 500 Over the Next 10 Years
Do you want to succeed in the stock market? Then I've got good news and bad news for you today. A column in The Wall Street Journal recently described a theoretically simple way to crush S&P 500 annual returns -- although that could be a lot harder than it looks in practice. (But don't fret.) The id...The Motley Fool
Wed, May 21
Could Buying This $4.1 Billion Stock Be Like Buying Berkshire Hathaway in 1965?
When Warren Buffett started buying shares of Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) in 1962, it was a failing textile business. The appeal for Buffett wasn't Berkshire's business -- it was that its book value far exceeded its stock price. Although he planned to sell the shares in 1964, a dis...The Motley Fool
Wed, May 21
LIVE MARKETS-Choppy waters now, but Europe bull case building - MS
STOXX 600 down 0.4%Crude prices jump, gold upMS upgrades EU banksWall St futures fallWelcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.comCHOPPY WATERS NOW, BUT EUROPE BULL CASE BUILDING -...Reuters
Wed, May 21
Prediction: These 3 Monster Dividend Stocks Will Continue Crushing the S&P 500 Beyond 2025
There are two basic ways to generate a return from holding stocks: capital gains and dividends. Capital gains are when investors get rewarded for a company's stock compounding in value, whereas dividends are when a company distributes a portion of its corporate profits directly to shareholders.Compa...The Motley Fool
Wed, May 21
Uni-Bio Science Group Receives NMPA Approval for 金因康® (Diquafosol Sodium Eye Drops), Advancing Dry Eye Syndrome Treatment in China
May 2025 – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”) proudly announces that its new ophthalmology product, 金因康® (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]. This milestone strengthens the Group’s portfolio in ophthalmology, addressing the growing demand for innovative treatments in China’s dry eye syndrome market, which affects an estimated 360 million individuals.As the Group's second ophthalmology drug following GeneSoft®, 金因康® addresses the underlying causes of dry eye syndrome by activating P2Y2 receptors to stimulate tear fluid and mucin secretion. It offers:Improved tear layer normalization and corneal epithelial repair. Treatment for patients with dry eye accompanied by abnormal tear-associated corneal epithelial defects. A next-generation option for more effective and patient-friendly care.China’s dry eye syndrome market is projected to surpass RMB 42 billion by 2030, growing at a CAGR of 28.4%, driven by increased screen time and evolving lifestyles. 金因康® is well-positioned to capture this growing demand with its proven efficacy and safety, widely recognized since the originator launched in Japan in 2010.To ensure rapid market penetration, the Group has expanded its sales force and integrated resources across hospitals, pharmacies, and e-commerce platforms. Strategic partnerships with API suppliers have secured high-quality raw materials at competitive costs, further enhancing 金因康®’s affordability and market competitiveness.Looking ahead, Uni-Bio Science Group will continue to focus on clinical needs and invest in R&D to expand its ophthalmic drug pipeline. With over 20 years of technological expertise, the Group is committed to delivering high-quality medical solutions, raising the standards of ophthalmic care, and solidifying its leadership in China's growing ophthalmology market.About Uni-Bio Science GroupUni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.About 金因康®Diquafosol Sodium Eye Drops are a medication for treating dry eye disease and are suitable for patients diagnosed with dry eye accompanied by abnormal tear-associated corneal epithelial defects. Diquafosol Sodium represents the next generation of dry eye medication, offering cutting-edge therapy through its novel mechanism as a P2Y2 receptor agonist, stimulating tear and mucin secretion. This addresses the underlying causes of dry eye syndrome, normalizing the tear layer and improving corneal epithelial damage.21/05/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Wed, May 21
CANADA STOCKS-TSX slips amid trade uncertainty, debate over Trump's tax bill
May 21 (Reuters) - Futures for Canada's main stock index dipped on Wednesday, retreating from a record peak in the previous session, as investors kept a cautious eye on trade developments and a debate over a sweeping U.S. tax bill.June futures on the S&P/TSX index .SXFcv1 were down 0.6% at 6...Reuters
Wed, May 21
American Crypto Innovation: 3 Made in America Crypto Stocks That Are Worthy of a Place in Your Portfolio
During the 2024 election, now-President Donald Trump promised a new pro-business approach for the crypto industry. That, combined with a complete rethinking of how global trade should work in 2025, is leading investors to focus on best-in-class crypto companies that are Made in America.Here are thre...The Motley Fool
Wed, May 21
TPG falls after $992 million secondary offering
** Alternative asset manager TPG's TPG.O shares fall 4.4% to $47.70 premarket** TPG late Tuesday announced pricing of secondary offering of 21 million shares at $47.25 apiece** DB Holdings, a vehicle for the benefit of the estate of TPG co-founder David Bonderman, sold all shares in the secondar...Reuters
Wed, May 21
Is Super Micro Computer a Better Stock Pick Than Nvidia?
Nvidia (NASDAQ: NVDA) has been a very successful stock pick over the past few years, but some are worried that it may be heading for some bumpy times. However, there's a strong trend toward more data center buildouts, as we're a long way from having artificial intelligence (AI) deployed to the scale...The Motley Fool
Wed, May 21
Could Warren Buffett's Last Move as Berkshire Hathaway CEO Be Buying This Beaten-Down "Magnificent Seven" Stock?
At the end of the year, Warren Buffett is due to step down as Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) CEO. Buffett has led this business for 60 years and has grown the small textile firm (its original business) into an investment giant. However, he's been a bit cautious lately and has grown...The Motley Fool
Wed, May 21
Should You Buy Lucid Group Stock While It's Below $5?
The stock of Lucid Group (NASDAQ: LCID) hasn't traded above the $5 mark since 2023. It's not entirely the electric-vehicle (EV) company's fault. Growth rates have been consistently positive, and analysts expect even more growth in 2025 and 2026 thanks to new model releases. In fact, there's a good c...The Motley Fool
Wed, May 21
MORNING BID AMERICAS-Bad week for bonds
By Mike Dolan LONDON, May 21 (Reuters) - What matters in U.S. and global markets todayBy Mike Dolan, Editor-At-Large, Financial Industry and Financial Markets In an already bad week for long bonds, an aggravated inflation picture around the world has added another irritant. I discuss this and...Reuters
Wed, May 21
Indonesia's antitrust body looking into risks from reported Grab-GoTo merger
JAKARTA, May 21 (Reuters) - Indonesia's antitrust agency has started research aimed at identifying risks from a possible merger between tech giants Grab GRAB.O and GoTo GOTO.JK, its head said on Wednesday.Muhammad Fanshurullah Asa in a statement said the agency would be able to conduct a thoroug...Reuters
Wed, May 21
Utility infra firm Centuri falls after pricing of secondary offering
** Shares of utility infrastructure services company Centuri CTRI.N fall 7.2% to $18.18 premarket** CTRI late Tuesday announced pricing of secondary offering of 9 million shares by top shareholder Southwest Gas SWX.N at $17.50 apiece** Offering priced at 10.7% discount to stock's last close** J....Reuters
Wed, May 21
